Resultado da Busca
23 de out. de 2020 · Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes ...
3 de dez. de 2020 · In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).
28 de ago. de 2021 · In the FIGARO-DKD trial, finerenone therapy improved cardiovascular outcomes, as compared with placebo, in patients with type 2 diabetes who had stage 2 to 4 CKD with moderately elevated ...
9 de fev. de 2021 · Compared with placebo, finerenone reduced the composite kidney and cardiovascular outcomes. We report the effect of finerenone on individual cardiovascular outcomes and in patients with and without history of atherosclerotic cardiovascular disease (CVD).
16 de nov. de 2020 · FIDELIO-DKD was a large trial investigating the effect of finerenone on heart and kidney outcomes in a broad but predominantly advanced CKD and T2D patient population.
29 de ago. de 2022 · The FIDELIO-DKD trial showed that finerenone has salutary effects on CV and renal outcomes among patients with T2DM and CKD, who were on a background of maximal RAS blockade therapy.
10 de fev. de 2022 · Abstract. Aims: The complementary studies FIDELIO-DKD and FIGARO-DKD in patients with type 2 diabetes and chronic kidney disease (CKD) examined cardiovascular and kidney outcomes in different, overlapping stages of CKD.
